US20050226827A1 - Skin lightening composition - Google Patents
Skin lightening composition Download PDFInfo
- Publication number
- US20050226827A1 US20050226827A1 US10/822,010 US82201004A US2005226827A1 US 20050226827 A1 US20050226827 A1 US 20050226827A1 US 82201004 A US82201004 A US 82201004A US 2005226827 A1 US2005226827 A1 US 2005226827A1
- Authority
- US
- United States
- Prior art keywords
- skin
- lightening composition
- skin lightening
- methyl sulfonyl
- sulfonyl methane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- the invention generally relates to a composition of matter, and in particular relates to a skin lightening composition for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation.
- Skin lighteners are used by millions of individuals for lightening their natural skin color for cosmetic reasons. Skin lighteners are also useful for treating the excessively dark skin color caused by a dermatological condition known as hyperpigmentation, characterized by abnormally increased pigmentation. A number of compounds are known to lighten skin tone when applied topically. The most popular of these is hydroquinone, which is safe, effective, and available without a prescription. Despite its overall safety and effectiveness, hydroquinone has been known to cause dermatological ochronosis, a progressive discoloration and degeneration of the skin, when used over an extended period of time.
- U.S. Pat. No. 6,328,987 to Marini appears to show a skin care composition for improving the appearance of aged or damaged skin, containing alpha interferon and optionally containing methyl sulfonyl methane.
- U.S. Pat. No. 4,296,130 to Herschler appears to show a method for softening skin and strengthening nails, comprising topically applying methyl sulfonyl methane to the skin and nails.
- the active ingredient of the skin lightening composition is methyl sulfonyl methane, which is highly effective in lightening the natural skin color of a user and for treating disorders of hyperpigmentation, and which is safe when topically applied to human skin.
- topical preparations of the skin lightening composition may be dissolved in a liquid solution, or in a carrier such as a cream, a lotion, or a gel.
- Orally ingestible preparations may be in liquid, tablet, capsule, or powder form).
- the invention is a skin lightening composition for lightening the natural skin color of a user, and for treating disorders of hyperpigmentation.
- the active ingredient is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound which may be safely administered topically or orally and which is highly effective for decreasing the ratio of dark melanin to light melanin, and thereby lightening the skin color of a user.
- the skin lightening composition additionally comprises a liquid solution or a cosmetic carrier such as a cream, a lotion, or a gel, for ease of topical application. Additionally, the skin lightening composition is provided in liquid or solid form for oral ingestion.
- Topical preparations of the skin lightening composition contain MSM in an amount equal to approximately 1 to 20 weight percent MSM relative to the weight of the entire composition.
- Orally ingestible preparations of the skin lightening composition contain approximately 200 mg to 5000 mg MSM per serving.
- the skin lightening composition according to the present invention is safe and effective for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation, which are characterized by abnormally increased pigmentation.
- the active ingredient of the skin lightening composition is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound found in the tissues and body fluids of higher mammals, and in fresh fruits and vegetables, meat, milk, seafood, and grains. Sulfur helps the body maintain the three dimensional conformation of proteins required for their proper activity. Sulfur is required for cell regeneration and collagen production in connective tissues of the skin, and in muscles, cartilage, organs and bone. MSM affects the synthesis of the melanin pigments, as will be described.
- MSM methyl sulfonyl methane
- Melanin is the pigment that largely determines skin color, and is synthesized by the melanocytes in the basal layer of the epidermis. There are two melanin pigments, eumelanin and pheomelanin. Eumelanin is black and pheomelanin is yellow. The ratio of these two pigments in the skin determines how dark or light the skin will be.
- the synthesis of eumelanin and pheomelanin requires the amino acid tyrosine and the enzyme tyrosinase. Tyrosinase catalyzes the conversion of tyrosine into biochemical intermediates dopa and dopaquinone.
- Dopaquinone is the precursor of both eumelanin and pheomelanin in the process of melanogenesis, the biochemical processes which synthesize the melanins. Differences in the ratio of melanin pigments create wide variations in human skin color, ranging from “white” skin color to “black” skin color. Darker skinned individuals have a higher eumelanin to pheomelanin ratio. To lighten skin color, the skin lightening composition targets melanogenesis. In particular, MSM causes dopaquinone to be diverted towards the production of pheomelanin, rather than eumelanin, by safely and effectively increasing intracellular sulfur levels.
- melanogenesis Under a high intracellular sulfur concentration, melanogenesis automatically leads to an increased synthesis of sulfhydryl-dopa conjugates resulting in the synthesis of the lighter colored pheomelanin instead of the darker colored eumelanin, which is the basis of the activity of MSM in the skin lightening composition.
- MSM has been previously used in supplements for treating acne, arthritis, muscle pain, and skin damage and aging. MSM can be used safely and effectively for lightening the natural skin color of a user and for treating disorders of hyperpigmentation.
- Methyl sulfonyl methane is all natural, nontoxic, non-allergenic, and non-pyretic, and is safe and effective when administered topically or when orally ingested, even over prolonged periods of time.
- MSM has no undesirable pharmacological effects when taken in conjunction with other substances.
- the skin lightening composition is provided in two types of preparations.
- the skin lightening composition is provided in topical preparations which are applied directly to the skin, and also in orally ingestible preparations.
- Topical preparations of the skin lightening composition comprise MSM dissolved or mixed within a vehicle.
- the vehicle may be a liquid solution, or it may be a cosmetic carrier such as a cream, a lotion, or a gel.
- Topical preparations of the skin lightening composition contain MSM at an amount equal to approximately 1 to 20 weight percent MSM relative to the weight of the entire skin lightening composition.
- Liquid solutions for topical application may include MSM in aqueous or non-aqueous solutions or emulsions.
- the skin lightening composition may be combined with other cosmetics, such as moisturizers or perfumes, in order to provide a skin lightening composition with properties in addition to its skin lightening properties.
- the skin whitening formula may comprises a moisturizing face and body cream into which the MSM has been blended.
- the skin lightening composition will be provided as a solid mixture, e.g. a mixture of MSM with vitamins and minerals that a user can mix with water and use for washing the face and body.
- the skin whitening formula may be supplied as a liquid solution which may be directly used as a face and body wash.
- Orally ingestible preparations of the skin lightening composition are provided in liquid or in solid form, and contain approximately 200 mg to 5000 mg MSM per serving.
- Orally ingestible preparations of the skin whitening formula may be in an edible form such as a tablet, a pill, a capsule, or in powder form.
- MSM can also be orally ingested in a nutritious mixture that contains vitamins, minerals, herbs, antioxidants, proteins, and/or amino acids.
- a skin lightening composition for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation.
- the invention is illustrated by example throughout the written description. It should be understood that numerous variations are possible, while adhering to the inventive concept. Such variations are contemplated as being a part of the present invention.
Abstract
A skin lightening composition for lightening the natural skin color of a user, and for treating disorders of hyperpigmentation. The active ingredient is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound which may be safely administered topically or orally and which is highly effective for decreasing the ratio of dark melanin to light melanin, and thereby lightening the skin color of a user. The skin lightening composition additionally comprises a liquid solution or a cosmetic carrier such as a cream, a lotion, or a gel, for ease of topical application. Additionally, the skin lightening composition is provided in liquid or solid form for oral ingestion. Topical preparations of the skin lightening composition contain MSM in an amount equal to approximately 1 to 20 weight percent MSM relative to the weight of the entire composition. Orally ingestible preparations of the skin lightening composition contain approximately 200 mg to 5000 mg MSM per serving.
Description
- 1. Field of the Invention
- The invention generally relates to a composition of matter, and in particular relates to a skin lightening composition for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation.
- 2. Description of the Related Art
- Skin lighteners are used by millions of individuals for lightening their natural skin color for cosmetic reasons. Skin lighteners are also useful for treating the excessively dark skin color caused by a dermatological condition known as hyperpigmentation, characterized by abnormally increased pigmentation. A number of compounds are known to lighten skin tone when applied topically. The most popular of these is hydroquinone, which is safe, effective, and available without a prescription. Despite its overall safety and effectiveness, hydroquinone has been known to cause dermatological ochronosis, a progressive discoloration and degeneration of the skin, when used over an extended period of time.
- Alternative compounds for lightening skin color are available. However, most of the synthetic or herbal compounds discovered have side effects and are not as effective as hydroquinone. Accordingly, there is a need for a skin lightening composition comprising methyl sulfonyl methane, a nontoxic, natural metabolite which is effective for lightening the natural skin color of a user and for treating disorders of hyperpigmentation, and which has no side effects.
- A variety of formulations have been devised for lightening skin, some which do not utilize hydroquinone. For example, U.S. Pat. No. 6,497,860 to Kawato appears to show a skin lightening composition comprising a reducing agent and a cosmetically acceptable carrier for the reducing agent, and which is substantially free of hydroquinone.
- A variety of formulations have been devised which contain methyl sulfonyl methane. By way of example, U.S. Pat. No. 6,328,987 to Marini appears to show a skin care composition for improving the appearance of aged or damaged skin, containing alpha interferon and optionally containing methyl sulfonyl methane. Additionally, U.S. Pat. No. 4,296,130 to Herschler appears to show a method for softening skin and strengthening nails, comprising topically applying methyl sulfonyl methane to the skin and nails. Furthermore, U.S. Pat. No. 6,573,299 to Petrus appears to show a method for the prevention and treatment of the aging eye by the application of a topical composition which optionally comprises methyl sulfonyl methane. Also, U.S. Pat. No. 4,477,469 to Herschler appears to show a preparation containing methyl sulfonyl methane that is applied topically, for softening skin and strengthening nails.
- While these formulations and methods of using formulations may be suitable for the particular purpose employed, or for general use, they would not be as suitable for the purposes of the present invention as disclosed hereafter.
- It is an object of the invention to provide a skin lightening composition which is effective in lightening the natural skin color of a user and for treating disorders of hyperpigmentation, and which is safe when topically applied to human skin. Accordingly, the active ingredient of the skin lightening composition is methyl sulfonyl methane, which is highly effective in lightening the natural skin color of a user and for treating disorders of hyperpigmentation, and which is safe when topically applied to human skin.
- It is another object of the invention to provide a skin lightening composition that is also safe and effective when orally ingested. Accordingly, methyl sulfonyl methane is a natural metabolite found in the human body, is nontoxic, and is suitable for long-term use by oral ingestion.
- It is yet another object of this invention to provide a skin lightening composition suitable for use with a wide variety of different cosmetic “carriers”, for ease of application to a user's skin. Accordingly, topical preparations of the skin lightening composition may be dissolved in a liquid solution, or in a carrier such as a cream, a lotion, or a gel. (Orally ingestible preparations may be in liquid, tablet, capsule, or powder form).
- The invention is a skin lightening composition for lightening the natural skin color of a user, and for treating disorders of hyperpigmentation. The active ingredient is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound which may be safely administered topically or orally and which is highly effective for decreasing the ratio of dark melanin to light melanin, and thereby lightening the skin color of a user. The skin lightening composition additionally comprises a liquid solution or a cosmetic carrier such as a cream, a lotion, or a gel, for ease of topical application. Additionally, the skin lightening composition is provided in liquid or solid form for oral ingestion. Topical preparations of the skin lightening composition contain MSM in an amount equal to approximately 1 to 20 weight percent MSM relative to the weight of the entire composition. Orally ingestible preparations of the skin lightening composition contain approximately 200 mg to 5000 mg MSM per serving.
- To the accomplishment of the above and related objects the invention may be embodied in the form described in the following description. Attention is called to the fact, however, that the examples given are illustrative only. Variations are contemplated as being part of the invention.
- The skin lightening composition according to the present invention is safe and effective for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation, which are characterized by abnormally increased pigmentation. The active ingredient of the skin lightening composition is methyl sulfonyl methane (MSM), a naturally occurring sulfur compound found in the tissues and body fluids of higher mammals, and in fresh fruits and vegetables, meat, milk, seafood, and grains. Sulfur helps the body maintain the three dimensional conformation of proteins required for their proper activity. Sulfur is required for cell regeneration and collagen production in connective tissues of the skin, and in muscles, cartilage, organs and bone. MSM affects the synthesis of the melanin pigments, as will be described.
- Melanin is the pigment that largely determines skin color, and is synthesized by the melanocytes in the basal layer of the epidermis. There are two melanin pigments, eumelanin and pheomelanin. Eumelanin is black and pheomelanin is yellow. The ratio of these two pigments in the skin determines how dark or light the skin will be. The synthesis of eumelanin and pheomelanin requires the amino acid tyrosine and the enzyme tyrosinase. Tyrosinase catalyzes the conversion of tyrosine into biochemical intermediates dopa and dopaquinone. Dopaquinone is the precursor of both eumelanin and pheomelanin in the process of melanogenesis, the biochemical processes which synthesize the melanins. Differences in the ratio of melanin pigments create wide variations in human skin color, ranging from “white” skin color to “black” skin color. Darker skinned individuals have a higher eumelanin to pheomelanin ratio. To lighten skin color, the skin lightening composition targets melanogenesis. In particular, MSM causes dopaquinone to be diverted towards the production of pheomelanin, rather than eumelanin, by safely and effectively increasing intracellular sulfur levels. Under a high intracellular sulfur concentration, melanogenesis automatically leads to an increased synthesis of sulfhydryl-dopa conjugates resulting in the synthesis of the lighter colored pheomelanin instead of the darker colored eumelanin, which is the basis of the activity of MSM in the skin lightening composition.
- MSM has been previously used in supplements for treating acne, arthritis, muscle pain, and skin damage and aging. MSM can be used safely and effectively for lightening the natural skin color of a user and for treating disorders of hyperpigmentation. Methyl sulfonyl methane is all natural, nontoxic, non-allergenic, and non-pyretic, and is safe and effective when administered topically or when orally ingested, even over prolonged periods of time. Moreover, MSM has no undesirable pharmacological effects when taken in conjunction with other substances.
- The skin lightening composition is provided in two types of preparations. In particular, the skin lightening composition is provided in topical preparations which are applied directly to the skin, and also in orally ingestible preparations. Topical preparations of the skin lightening composition comprise MSM dissolved or mixed within a vehicle. The vehicle may be a liquid solution, or it may be a cosmetic carrier such as a cream, a lotion, or a gel. Topical preparations of the skin lightening composition contain MSM at an amount equal to approximately 1 to 20 weight percent MSM relative to the weight of the entire skin lightening composition. Liquid solutions for topical application may include MSM in aqueous or non-aqueous solutions or emulsions. It is contemplated that the skin lightening composition may be combined with other cosmetics, such as moisturizers or perfumes, in order to provide a skin lightening composition with properties in addition to its skin lightening properties. By way of example, the skin whitening formula may comprises a moisturizing face and body cream into which the MSM has been blended. It is additionally contemplated that the skin lightening composition will be provided as a solid mixture, e.g. a mixture of MSM with vitamins and minerals that a user can mix with water and use for washing the face and body. Alternately, the skin whitening formula may be supplied as a liquid solution which may be directly used as a face and body wash.
- Orally ingestible preparations of the skin lightening composition are provided in liquid or in solid form, and contain approximately 200 mg to 5000 mg MSM per serving. Orally ingestible preparations of the skin whitening formula may be in an edible form such as a tablet, a pill, a capsule, or in powder form. MSM can also be orally ingested in a nutritious mixture that contains vitamins, minerals, herbs, antioxidants, proteins, and/or amino acids.
- In conclusion, herein is presented a skin lightening composition for lightening the natural skin color of a user, and also for treating disorders of hyperpigmentation. The invention is illustrated by example throughout the written description. It should be understood that numerous variations are possible, while adhering to the inventive concept. Such variations are contemplated as being a part of the present invention.
Claims (10)
1. A topical preparation of a skin lightening composition, suitable for direct application to the face and body of a user, for lightening the natural skin color of the user and for treating disorders of hyperpigmentation, comprising:
methyl sulfonyl methane, a naturally occurring sulfur compound which lightens the skin; and
a vehicle; and
wherein the methyl sulfonyl methane is dissolved within the vehicle at an amount equal to approximately 1 to 20 weight percent methyl sulfonyl methane relative to the weight of the entire skin lightening composition.
2. The topical preparation of a skin lightening composition as recited in claim 1 , wherein the vehicle is a liquid solution.
3. The topical preparation of a skin lightening composition as recited in claim 2 , further comprising a perfume.
4. The topical preparation of a skin lightening composition as recited in claim 3 , further comprising a nutrient chosen from a class of nutrients consisting of vitamins and minerals.
5. The topical preparation of a skin lightening composition as recited in claim 1 , wherein the vehicle is a cosmetic carrier chosen from a class of cosmetic carriers consisting of creams, lotions, and gels, wherein the methyl sulfonyl methane is blended within said cosmetic carrier at an amount equal to approximately 1 to 20 weight percent methyl sulfonyl methane relative to the weight of the entire skin lightening composition.
6. The topical preparation of a skin lightening composition as recited in claim 5 , further comprising a perfume.
7. The topical preparation of a skin lightening composition as recited in claim 6 , further comprising a nutrient chosen from a class of nutrients consisting of vitamins and minerals.
8. An orally ingestible preparation of a skin lightening composition, comprising:
approximately 200 mg to 5000 mg methyl sulfonyl methane per serving; and
an edible form chosen from a class of edible forms consisting of tablets, pills, capsules, and powders; and
wherein the methyl sulfonyl methane is contained within the edible form.
9. The orally ingestible preparation of a skin whitening formula as recited in claim 8 , further comprising at least one nutrient chosen from a class of nutrients consisting of vitamins, minerals, antioxidants, proteins, and amino acids, and wherein said at least one nutrient is contained within the edible form.
10. A method for lightening the natural skin color of a user and for treating disorders of hyperpigmentation, utilizing a topical preparation of a skin lightening composition comprising methyl sulfonyl methane and a vehicle, wherein the methyl sulfonyl methane is dissolved within the vehicle at an amount equal to approximately 1 to 20 weight percent methyl sulfonyl methane relative to the weight of the entire skin lightening composition, said method comprising the step of directly applying the skin lightening composition to the face and body of a user, and thereby lightening the skin of the face and the body.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/822,010 US20050226827A1 (en) | 2004-04-09 | 2004-04-09 | Skin lightening composition |
US10/599,779 US8293801B2 (en) | 2004-04-09 | 2005-04-08 | Skin lightening method |
PCT/US2005/011915 WO2005099657A1 (en) | 2004-04-09 | 2005-04-08 | Skin lightening method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/822,010 US20050226827A1 (en) | 2004-04-09 | 2004-04-09 | Skin lightening composition |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10599779 Continuation | 2007-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050226827A1 true US20050226827A1 (en) | 2005-10-13 |
Family
ID=35060766
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/822,010 Abandoned US20050226827A1 (en) | 2004-04-09 | 2004-04-09 | Skin lightening composition |
US10/599,779 Expired - Fee Related US8293801B2 (en) | 2004-04-09 | 2005-04-08 | Skin lightening method |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/599,779 Expired - Fee Related US8293801B2 (en) | 2004-04-09 | 2005-04-08 | Skin lightening method |
Country Status (2)
Country | Link |
---|---|
US (2) | US20050226827A1 (en) |
WO (1) | WO2005099657A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281822A1 (en) * | 2005-04-20 | 2006-12-14 | Cardinal Associates, Inc. | Treatment and prevention of elevated homocysteine |
US20080260871A1 (en) * | 2007-04-18 | 2008-10-23 | Fruitman Clinton O | Method and composition for infusing herbal extracts and pharmaceuticals through the skin |
US7955418B2 (en) | 2005-09-12 | 2011-06-07 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same |
US8435224B2 (en) | 2005-09-12 | 2013-05-07 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US8673061B2 (en) | 2005-09-12 | 2014-03-18 | Abela Pharmaceuticals, Inc. | Methods for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
US9839609B2 (en) | 2009-10-30 | 2017-12-12 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2472379A (en) * | 2009-07-15 | 2011-02-09 | Oskia Skincare Ltd | Topical cosmetic formulation comprising MSM, a vitamin and a carbohydrate |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4296130A (en) * | 1979-08-30 | 1981-10-20 | Herschler R J | Methylsulfonylmethane and methods of use |
US5071878A (en) * | 1979-08-30 | 1991-12-10 | Herschler R J | Use of methylsulfonylmethane to enhance diet of an animal |
US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US6373299B1 (en) * | 2000-12-04 | 2002-04-16 | Motorola, Inc. | Electric driver circuit and method |
US20020142019A1 (en) * | 2000-09-08 | 2002-10-03 | Kuhnau Steven C. | Cosmetic composition, method of use and method of making |
US6541045B1 (en) * | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005279A1 (en) * | 1992-09-04 | 1994-03-17 | Aws Shakir Mustafa Salim | Dermatological treatment compositions containing dimethylsulphone and a sulfur containing amino acid |
US6497860B1 (en) | 1996-11-04 | 2002-12-24 | Children's Hospital Medical Center | Skin lightening compositions |
JP2002519366A (en) * | 1998-07-07 | 2002-07-02 | トランスダーマル・テクノロジーズ・インコーポレーテツド | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents, and methods of dispensing such compositions and their delivery |
US6573299B1 (en) * | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
US6328987B1 (en) | 2000-11-03 | 2001-12-11 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions containing alpha interferon |
-
2004
- 2004-04-09 US US10/822,010 patent/US20050226827A1/en not_active Abandoned
-
2005
- 2005-04-08 WO PCT/US2005/011915 patent/WO2005099657A1/en active Application Filing
- 2005-04-08 US US10/599,779 patent/US8293801B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4296130A (en) * | 1979-08-30 | 1981-10-20 | Herschler R J | Methylsulfonylmethane and methods of use |
US5071878A (en) * | 1979-08-30 | 1991-12-10 | Herschler R J | Use of methylsulfonylmethane to enhance diet of an animal |
US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US20020142019A1 (en) * | 2000-09-08 | 2002-10-03 | Kuhnau Steven C. | Cosmetic composition, method of use and method of making |
US6373299B1 (en) * | 2000-12-04 | 2002-04-16 | Motorola, Inc. | Electric driver circuit and method |
US6541045B1 (en) * | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060281822A1 (en) * | 2005-04-20 | 2006-12-14 | Cardinal Associates, Inc. | Treatment and prevention of elevated homocysteine |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US7955418B2 (en) | 2005-09-12 | 2011-06-07 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same |
US8298320B2 (en) | 2005-09-12 | 2012-10-30 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
US8435224B2 (en) | 2005-09-12 | 2013-05-07 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US8440001B2 (en) | 2005-09-12 | 2013-05-14 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same |
US8673061B2 (en) | 2005-09-12 | 2014-03-18 | Abela Pharmaceuticals, Inc. | Methods for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US9186297B2 (en) | 2005-09-12 | 2015-11-17 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds |
US9186472B2 (en) | 2005-09-12 | 2015-11-17 | Abela Pharmaceuticals, Inc. | Devices for removal of dimethyl sulfoxide (DMSO) or related compounds or associated odors and methods of using same |
US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
US20080260871A1 (en) * | 2007-04-18 | 2008-10-23 | Fruitman Clinton O | Method and composition for infusing herbal extracts and pharmaceuticals through the skin |
US9839609B2 (en) | 2009-10-30 | 2017-12-12 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
US9855212B2 (en) | 2009-10-30 | 2018-01-02 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases |
US10596109B2 (en) | 2009-10-30 | 2020-03-24 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2005099657A1 (en) | 2005-10-27 |
US8293801B2 (en) | 2012-10-23 |
US20070264212A1 (en) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100952109B1 (en) | Personal care compositions comprising a dipeptide | |
US8293801B2 (en) | Skin lightening method | |
KR20200074176A (en) | Cosmetic composition comprising nicotinamide mononucleotide | |
CN103025307B (en) | Chicoric acid and derivant are used for the purposes for adjusting cutaneous pigmentation | |
CN101827579A (en) | Novel use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same | |
US20080095732A1 (en) | Personal care compositions | |
KR20140008234A (en) | Whitening cosmetic compounds | |
US20140271509A1 (en) | Compositions for Skin Lightening and/or Brightening | |
CN103025308B (en) | Caftaric acid and derivative are used for the purposes for adjusting cutaneous pigmentation in food supplement | |
KR100837879B1 (en) | Cosmetic Composition Containing Collagen from Deer Extracts and Process for Preparation Thereof | |
KR20070118719A (en) | Skin topical composition containing epidermal growth factor and fibroblast growth factor | |
KR20090091505A (en) | Composition for skin whitening containing oxygen dissolving water | |
KR102349988B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dehydrocorydaline or a pharmaceutically acceptable salt thereof | |
JP7132561B2 (en) | Melanin production inhibitor | |
AU2014271339B2 (en) | Personal care compositions | |
KR102348148B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dihydroartemisinin | |
KR20220078294A (en) | A composition for promoting melanin synthesis comprising didymin | |
JP2022164564A (en) | Skin-whitening composition and skin-whitening method utilizing the same | |
CN1270801A (en) | Use of unfermented honey as decolouring agent | |
KR20220078295A (en) | A composition for promoting melanin synthesis comprising linarin | |
JP2024045354A (en) | Cosmetic composition, screening method and cosmetic method | |
KR20220078293A (en) | A composition for promoting melanin synthesis comprising chrysoeriol | |
WO2010049463A1 (en) | Depigmenting topical compositions and their uses | |
KR20190124851A (en) | Composition for skin whitening comprising citron seed oil and peptide for collagen activation as effective component | |
JP2006083070A (en) | Active oxygen scavenger, bleaching agent, anti-inflammatory agent, collagenase activity inhibitor or collagenase production inhibitor comprising calycinal extract of diospyros kaki l as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THIENNA, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HO, THIENNA;REEL/FRAME:016429/0197 Effective date: 20050323 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |